Consultation: formulary amendments April 2023

The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of the proposed formulary amendments in the attached consultation document.

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.

Please use this form to submit comments. All comments will be reviewed but please do not expect a personal response as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.

Please note

1. The messages sent from this form are transmitted via our hosts web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net.
2. This consultation will run for four weeks and closes at 5pm on Friday 2nd June 2023.

Name *

Email *

Email

Confirm Email

Job title *

Employer *

Locality

Are you responding on behalf of an organisation or as an individual? *

• On behalf of an organisation or organisational leader
• As an individual

Please specify who you are responding for, including job title and organisation as appropriate (e.g. on behalf of chief pharmacist of ABC NHS Foundation Trust) *

1a. NICE did not make a recommendation on trastuzumab deruxtecan in TA879 so it will not be added to formulary in this indication. Does this create any clinical or commissioning problems? *

• Yes (please specify below)
• No
• Not applicable

1b. What issues would lack of access create? If a specific patient group requires access, please define it and estimate the number of people affected.

----------------------------------------------------------------------------------------------------------------------------------------

2a. Can your organisation provide access to tezepelumab, as recommended in NICE TA880, within the implementation period? *

• Yes
• No (please specify below)
• Not applicable

2b. Is the proposed RAG status appropriate?

• Yes
• No (please specify below)

2c. Please provide detail on the barriers to providing access and how they might be addressed, and/or suggested changes to the proposed RAG status

----------------------------------------------------------------------------------------------------------------------------------------

Do you have any additional comments?

Submit